11/20/2025
Big News! CaNVAS Receives NIH U54 Award to Launch ARDVARC 💙❤️
We are thrilled to share that the CaNVAS Consortium has been awarded a prestigious NIH U54 grant to launch ARDVARC – Advancing Rare Disorders–Vascular mAlformation Research Network with CaNVAS. ‼️
Vascular malformations are rare conditions caused by abnormal growth of blood or lymphatic vessels. They can be painful, disfiguring, and life-altering, yet no cures exist and treatment options remain extremely limited. ARDVARC aims to change that.
What ARDVARC Will Do🤔
With support from the NIH and built on the strength of all CaNVAS academic medical centers, ARDVARC will:
⭐️Build the first U.S. centralized natural history registry and biorepository for complex vascular malformations
⭐️Develop new patient-reported outcome measures to better understand quality of life for children with VMs
⭐️Create a national infrastructure for future clinical trials
⭐️Support innovative pilot studies aimed at accelerating treatment development
⭐️Train and grow the next generation of VM experts through a dedicated Career Enhancement Core
⭐️Bring together clinicians, researchers, basic scientists, and patient advocacy groups to collaborate as one interdisciplinary team
Why This Matters ❓
Complex vascular malformations—including PIK3CA-related overgrowth spectrum (PROS), complex lymphatic anomalies, and extracranial arteriovenous malformations—are rare but devastating disorders. Families often struggle for years without answers, and many patients face pain, bleeding, disfigurement, or organ damage.
ARDVARC’s long-term goal is clear:
Improve outcomes, accelerate clinical trials, and ultimately identify cures.
This award marks a landmark moment for the VM community, and we are incredibly proud of the CaNVAS network and all our partners who made this possible. The work begins now — and we’re just getting started.